Gastrointestinal and hepatic manifestations of human ehrlichiosis: 8 cases and a review of the literature.
BACKGROUND
Ehrlichiosis has emerged as an increasingly recognized tick-borne rickettsial disease. It can affect multiple organs including the gastrointestinal tract and liver. Signs and symptoms include abdominal pain, nausea, vomiting, diarrhea, jaundice, and hepatosplenomegaly. Patients commonly have elevated liver transaminases early in the course of illness as well as leukopenia and thrombocytopenia. If not diagnosed and treated in a timely fashion, ehrlichiosis can progress to multiorgan failure.


METHODS
Between 1992 and 1998, 8 patients meeting the CDC criteria for ehrlichiosis were diagnosed and treated at the John L. McClellan Memorial Veterans Hospital and University Hospital in Little Rock, Ark. These cases and English-language articles relating to gastrointestinal and hepatic manifestations of ehrlichiosis, identified by searching Medline and manually reviewing bibliographies of retrieved articles, are reviewed.


RESULTS
Seven of the eight patients had elevated transaminases on presentation which increased rapidly initially and slowly returned to normal. Three of our patients had hyperbilirubinemia. One of the eight patients presented with hepatomegaly. Three had hyperbilirubinemia with a peak bilirubin of 13.8 mg/dl. Two patients (25%) had a rash on presentation. All 8 patients were treated with and responded to doxycycline. One developed multiorgan failure but eventually recovered with intensive medical care and doxycycline.


CONCLUSIONS
To avoid treatment delay and serious complications, in the appropriate clinical setting ehrlichiosis should be considered as a cause of elevated liver transaminases.
Nutt
A K
AK
Division of Gastroenterology, John L. McClellan Memorial Veterans Hospital and University of Arkansas for Medical Sciences, Little Rock, Ark. 72205-7199, USA.
Raufman
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000710:Anaplasmataceae / Q000145:classification; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D018469:Ehrlichia chaffeensis; D016873:Ehrlichiosis / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000097:blood / Q000175:diagnosis / Q000382:microbiology*; D006403:Hematologic Tests; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000175:diagnosis / Q000382:microbiology*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D000637:Transaminases / Q000097:blood; D014481:United States / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D000637:Transaminases; D004318:Doxycycline